Agonists of peroxisome proliferator-activated receptor gamma (PPARγ), including pioglitazone and rosiglitazone, have demonstrated significant anti-tumor effects in ACC through multiple mechanisms in preclinical studies. Here, PPARG is linked to adrenal cortex carcinoma.